Emerging options in growth hormone therapy: An update

Drug Design, Development and Therapy

Volumn 5, Issue , 2011, Pages 411-419

  Kemp, Stephen F ^a   Paul Frindik, J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Anabolic; Growth hormone; Short stature; Somatotropin

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE; PLACEBO;

AGING; BONE DYSPLASIA; BONE TUMOR; BURN; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; COLORECTAL CANCER; CRITICALLY ILL PATIENT; CYSTIC FIBROSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEVER; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; GENE; GENE FREQUENCY; GENE MUTATION; GROWTH HORMONE DEFICIENCY; GYNECOMASTIA; HEADACHE; HODGKIN DISEASE; HORMONAL THERAPY; HUMAN; INJECTION SITE REACTION; INTERMETHOD COMPARISON; INTRACRANIAL HYPERTENSION; LENGTH OF STAY; LOW DRUG DOSE; MOLECULAR PATHOLOGY; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PHYSICAL PERFORMANCE; PREDICTION; PSYCHOLOGICAL ASPECT; RECOMMENDED DRUG DOSE; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SHORT STATURE; SHOX GENE; SIDE EFFECT; SILVER RUSSELL SYNDROME; SLIPPED CAPITAL FEMORAL EPIPHYSIS; X LINKED HYPOPHOSPHATEMIC RICKETS; BODY HEIGHT; DRUG APPROVAL; GROWTH DISORDER; UNITED STATES;

BODY HEIGHT; DRUG APPROVAL; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84856205865     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S23140     Document Type: Review

References (87)

1. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958;18(8):901-903.
2. Frasier SD. The not-so-good old days: working with pituitary growth hormone in North America, 1956-1985. J Pediatr. 1997;131(1 Pt 2): S1-S4.
3. Hintz RL. The prismatic case of Creutzfeldt-Jacob disease associated with primary growth hormone treatment. J Clin Endocrinol Metab. 1995;80(8):2298-2301.
4. Goeddel DV, Heyneker HL, Hozumi T, et al. Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature. 1979;281(5732):544-548.
5. Flodh H. Human growth hormone produced with recombinant DNA technology: development and production. Acta Paediatr Scand Suppl. 1986;325:1-9.
6. Massa GG, Vanderschueren-Lodeweyckx M, Bouillon R. Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin Endocrinol (Oxf). 1993;38(2):137-142.
7. Franklin SL, Geffner ME. Growth hormone: the expansion of available products and indications. Endocrinol Metab Clin North Am. 2009;38(3): 587-611.
8. Wilson DM, Baker B, Hintz RL, Rosenfeld RG. Subcutaneous versus intramuscular growth hormone therapy: growth and acute somatomedin response. Pediatrics 1985;76(3):361-364.
9. Milner RD, Russell-Fraser T, Brook CG, et al. Experience with human growth hormone in Great Britain: the report of the MRC Working Party. Clin Endocrinol (Oxf). 1979;11(1):15-38.
10. Albertsson-Wikland K, Westphal O, Westgren U. Daily subcutaneous administration of human growth hormone in growth hormone deficient children. Acta Paediatr Scand. 1986;75(1):89-97.
11. Jorgensen JO, Moller N, Laruritzen T, Alberti KG, Orskov H, Christiansen JS. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab. 1990;70(1):207-214.
12. Kastrup KW, Christiansen JS, Andersen JK, Orskov H. Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children. Acta Endocrinol (Copenh). 1983;104(2):148-152.
13. MacGillivray MH, Baptista J, Johanson A. Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group. J Clin Endocrinol Metab. 1996;81(5): 1806-1809.
14. Blethen SL, Baptista J, Kuntzie J, Foley T, LaFranchi S, Johanson A. Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. The Genentech Growth Study Group. J Clin Endocrinol Metab. 1997;82(2):418-420.
15. Frindik JP, Baptista J. Adult height in growth hormone deficiency: historical perspective and examples from the national cooperative growth study. Pediatrics. 1999;104(4 Pt 2):1000-1004.
16. Maghnie M, Ambrosini L, Cappa M, et al. Adult heights in patients with permanent growth hormone deficiency with and without multiple pituitary hormone deficiencies. J Clin Endocrinol Metab. 2006;91(8): 2900-2905.
17. Richmond EJ, Rogol AD. Current indications for growth hormone therapy for children and adolescents. In: Hindmarsh PC, editor. Current Indications for Growth Hormone Therapy. Vol 18. 2nd ed. Basel: Karger; 2010:92-108.
18. Hintz RL. Current and potential therapeutic uses of growth hormone and insulin-like growth factor I. Endocrinol Metab Clin North Am. 1996;25(3):759-773.
19. Rao E, Weiss B, Fukami M, et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet. 1997;16(1):54-63.
20. Ogata T. SHOX: pseudoautosomal homeobox containing gene for short stature and dyschondrosteosis. Growth Horm IGF Res. 1999;9 (Suppl B):53-57.
21. Binder G, Schwarze CP, Ranke MB. Identification of short stature caused by SHOX defects and therapeutic effect of recombinant human growth hormone. J Clin Endocrinol Metab. 2000;85(1):245-249.
22. Kofoed EM, Hwa V, Little B, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med. 2003;349(12): 1139-1147.
23. Domene HM, Bengolea SV, Martinez AS, et al. Def iciency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit. N Engl J Med. 2004;350(6): 570-577.
24. Salerno M, Balestrieri B, Matrecano E, et al. Abnormal GH receptor signalling in children with idiopathic short stature. J Clin Endocrinol Metab. 2001;86(8):3882-3888.
25. Savage MO, Camacho-Hübner C, David A, et al. Idiopathic short stature: will genetics influence the choice between GH and IGF-I therapy? Eur J Endocrinol. 2007;157(Suppl 1):S33-S37.
26. Rosenfeld RG. The molecular basis of idiopathic short stature. Growth Horm IGF Res. 2005;15 (Suppl A):S3-S5.
27. Kemp SF, Kuntzie J, Attie KM, et al. Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab. 2005;90(9):5247-5253.
28. Kemp SF, Dana K, Frane J, Lippe B. Idiopathic Short Stature (ISS): What has changed since FDA approval of growth hormone (GH) for this diagnosis? Data from the Genentech (GNE) National Cooperative Growth Study (NCGS). Paper presented at the Annual Meeting of The Endocrine Society, June 2-3, 2007; Toronto, Canada.
29. Ross JL, Kowal K, Quigley CA, et al. The phenotype of short stature homeobox gene (SHOX) deficiency in childhood: contrasting children with Leri-Weill dyschondrosteosis and Turner Syndrome. J Pediatr. 2005;147(4):499-507.
30. Bang P, Bjerknes R, Dahlgren J, et al. A comparison of different definitions of growth response in short prepubertal children treated with growth hormone. Horm Res Paediatr. 2011;75(5):335-345.
31. Hertel NT, Eklöf O, Ivarsson S, et al. Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial. Acta Paediatr. 2005;94(10):1402-1410.
32. Toumba M, Albanese A, Azcona C, Stanhope R. Effect of long-term growth hormone treatment on final height of children with Russell-Silver syndrome. Horm Res Paediatr. 2010;74(3):212-217.
33. Saggese G, Baroncelli GI, Barsanti S. Growth hormone treatment of familial hypophosphatemic rickets. Arch Pediatr. 1998;5(Suppl 4): 360S-363S.
34. Saggese G, Baroncelli GI, Bartellone S, Perri G. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: Effect on growth mineral metabolism, and bone density. J Pediatr. 1995;127(3):395-402.
35. Reusz GS, Miltényi G, Stubnya G, et al. X-linked hypophosphatemia: effects of treatment with recombinant human growth hormone. Pediatr Nephrol. 1997;11(5):573-577.
36. Wilson DM. Growth hormone and hypophosphatemic rickets. J Pediatr Endocrinol Metab. 2000;13(Suppl 2):993-998.
37. Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G. Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr. 2001;138(2):236-243.
38. Huiming Y, Chaomin W. Recombinant growth hormone therapy for X-linked hypophosphatemia in children. Cochrane Database Syst Rev. 2005;Jan 25(1):CD004447.
39. Ross JL, Sandberg DE, Rose SR, et al. Psychological adaptation in children with idiopathic short stature treated with growth hormone or placebo. J Clin Endocrinol Metab. 2004;89(10):4873-4878.
40. Gordon M, Crouthamel C, Post EM, Richman RA. Psychological aspects of constitutional short stature: social competence, behavior problems, self-esteem, and family functioning. J Pediatr. 1982;101(3): 477-480.
41. Siegal PT, Clopper RR, Stabler B. Psychological impact of significantly short stature. Acta Paediatr Scand Suppl. 1991;377:14-18.
42. Stabler B, Clopper RR, Siegal PT, Stoppani C, Compton PG, Underwood LE. Academic achievement and psychological adjustment in short children: the national cooperative growth study. J Dev Behav Pediatr. 1994;15(1):1-6.
43. Steinhausen HC, Dorr HG, Kannenberg R, Malin Z. The behavior profile of children and adolescents with short stature. J Dev Behav Pediatr. 2000;21(6):423-428.
44. Downie AB, Mulligan J, Stratford RJ, Betts PR, Voss LD. Are short normal children at a disadvantage? The Wessex growth study. BMJ. 1997;314(7074):97-100.
45. Skuse D, Gilmour J, Tian CS, Hindmarsh PC. Psychological assessment of children with short stature: a preliminary report. Acta Paediatr Suppl. 1994;406:11-16.
46. Voss LD. Short normal stature and psychological disadvantage: a critical review of the evidence. J Pediatr Endocrinol Metab. 2001; 14(6):701-711.
47. Voss LD, Bailey BJ, Mulligan J, Wilkin TJ, Betts PR. Short stature and school performance-the Wessex growth study. Acta Paediatr Scand Suppl. 1991;377:29-31.
48. Kranzler JH, Rosenbloom AL, Proctor B, Diamond FB. Is short stature a handicap? A comparison of the psychosocial functioning of referred and nonreferred children with normal short stature and children with normal stature. J Pediatr. 2000;136(1):96-102.
49. Stabler B. Growth hormone insufficiency during childhood has implications for later life. Acta Paediatr Scand Suppl. 1991;377: 9-13.
50. Underwood LE. The social cost of being short: societal perceptions and biases. Acta Paediatr Scand Suppl. 1991;377:3-8.
51. Sandberg DE, Bukowski WM, Fung CM, Noll RB. Height and social adjustment: are extremes a cause for concern and action? Pediatrics. 2004;114(3):744-750.
52. Visser-van Balen H, Sinnema G, Geenen R. Growing up with idiopathic short stature: psychosocial development and hormone treatment: a critical review. Arch Dis Child. 2006;91(5):433-439.
53. Kemp SF. Height and social adjustment. Pediatrics. 2005;115(2): 515-516.
54. Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology workshop. J Clin Endocrinol Metab. 2008; 93(11):4210-4217.
55. Cosgrove C, Cohen S. Normal at Any Cost: Tall Girls, Short Boys, and the Medical Industry's Quest to Manipulate Height. New York, NY: Penguin Group; 2009.
56. Brutt AL, Sandberg DE, Chaplin J, et al. Assessment of health-related quality of life and patient satisfaction in children and adolescents with growth hormone deficiency or idiopathic short stature-Part 1: a critical evaluation of available tools. Horm Res. 2009;72(2):65-73.
57. Bullinger M, Koltowska-Haggstrom M, Sandberg DE, et al. Healthrelated quality of life of children and adolescents with growth hormone deficiency or idiopathic short stature-Part 2: available results and future directions. Horm Res. 2009;72(2):74-81.
58. Chaplin JE, Kriström B, Jonsson B, et al. Improvements in behaviour and self-esteem following growth hormone treatment in short prepubertal children. Horm Res Paediatr. 2011;75(4):291-303.
59. Lee JM, Davis MM, Clark SJ, Hofer TP, Kemper AR. Estimated costeffectiveness of growth hormone therapy for idiopathic short stature. Arch Pediatr Adolesc Med. 2006;160(3):263-269.
60. Savage MO. Should idiopathic short stature be treated with growth hormone? Nat Clin Pract Endocrinol Metab. 2009;5(3):148-149.
61. Frindik JP, Kemp SF. Managing idiopathic short stature: role of somatropin (rDNA origin) for injection. Biologics. 2010;4:147-155.
62. Hardin DS, Ellis K, Dyson M, McConnel R, Rice J, Seilheimer DK. Growth hormone improves clinical status in children with cystic fibrosis: results of a randomized controlled trial. J Pediatr. 2001;139(5): 636-642.
63. Hardin DS, Rice J, Ahn C, et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. J Pediatr. 2005;146(3):324-328.
64. Ruokonen E, Takala J. Dangers of growth hormone therapy in critically ill patients. Curr Opin Clin Nutr Metab Care. 2002;5(2):199-209.
65. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999;341(11):785-792.
66. Herndon DN, Barrow RE, Kunkel KR, Broemeling L, Rutan RL. Effects of recombinant human growth hormone on donor-site healing in severely burned children. Ann Surg. 1990;212(4):424-429.
67. Lal SO, Wolf SE, Herndon DN. Growth hormone, burns and tissue healing. Growth Horm IGF Res. 2000; (Suppl B 10):S39-S43.
68. Cummings DE, Merriam GR. Growth hormone therapy in adults. Annu Rev Med. 2003;54:513-533.
69. Lanfranco F, Gianotti L, Giordano R, Pellegrino M, Maccario M, Arvat E. Ageing, growth hormone and physical performance. J Endocrinol Invest. 2003;26(9):861-872.
70. Sattler FR, Bhasin S, He J, et al. Durability of the effects of testosterone and growth hormone supplementation in older community dwelling men: The HORMA trial. Clin Endocrinol (Oxf). Mar 4, 2011. doi: 10.1111/j.1365-2265.2011.04014.x.
71. Savine R, Sönksen PH. Is the somatopause an indication for growth hormone replacement? J Endocrinol Invest. 1999;22(Suppl 5):142-149.
72. Birzniece V, Nelson AE, Ho KKY. Growth hormone and physical performance. Trends Endocrinol Metab. 2011;22(5):171-178.
73. Yarasheski KE, Campbell JA, Smith K, Rennie MJ, Holloszy JO, Bier DM. Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol. 1992;262(3 Pt 1):E261-267.
74. Yarasheski KE, Zachweija JJ, Angelopoulos TJ, Bier DM. Short-term growth hormone treatment does not increase muscle protein synthesis in experienced weight lifters. J Appl Physiol. 1993;74(6):3073-3076.
75. Krysiak R, Gdula-Dymek A, Bednarska-Czerwińska A, Okopień B. Growth hormone therapy in children and adults. Pharmacol Rep. 2007; 59(5):500-516.
76. Festen DA, van Toorenenbergen A, Duivenvoorden HJ, Hokken-Koelega AC. Adiponectin level in prepubertal children with Prader-Willi syndrome before and after growth hormone therapy. J Clin Endocrinol Metab. 2007;92(4):1549-1554.
77. Root AW, Root MJ. Clinical pharmacology of human growth hormone and its secretagogues. Curr Drug Targets Immune Endocr Metabol Disord. 2002;2(1):27-52.
78. Quigley CA, Gill AM, Crowe BJ, et al. Safety of growth hormone treatment in pediatric patients with idiopathic short stature. J Clin Endocrinol Metab. 2005;90(9):5188-5196.
79. Leschek EW, Rose SR, Yanovski JA, et al. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(7):3140-3148.
80. Wit JM, Rekers-Mombarg LTM, Cutler GB Jr, et al. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. J Pediatr. 2005;146(1):45-53.
81. Renehan AG, Brennan BM. Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab. 2008;22(4):639-657.
82. Gunnell D, Okasha M, Smith GD, Oliver SE, Sandju J, Holly JM. Height, leg length, and cancer risk: a systematic review. Epidemiol Rev. 2008;23(2):313-342.
83. Rowlands MA, Gunnell D, Harris R, J. VL, Holly JM, Martin RM. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review adn meta-analysis. Int J Cancer. 2009;124(10): 2416-2429.
84. Peyrat JP, Bonneterre J, Hecquet B, et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer. 1993;29A(4):492-497.
85. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet. 2002;360(9329):273-277.
86. Carel JC, Butler G. Safety of recombinant human growth hormone. Endocr Dev. 2010;18:40-54.
87. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3(70):70ra13.